Dallas, TX -- (SBWIRE) -- 03/18/2015 -- IRBP is producing RAVAX, a Phase III, potential first-in-class vaccine for the treatment of patients with early RA or with RA for less than 10 years. RAVAX is a vaccine that contains four 17-20mer (amino acids) (IR501) or 40mer (IR703) peptides against the T-cell receptor, specifically targetting autoreactive T cells, thus reducing their activity. The RAVAX vaccine is believed to target autoreactive T cells, while not affecting normal cells (IRBP, 2014b). Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023.

Complete report is available
http://www.rnrmarketresearch.com/ravax-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-market-report.html

The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Scope
-Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

-Detailed information on RAVAX including product description, safety and efficacy profiles as well as a SWOT analysis

Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return.

-Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.

-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.

-Make more informed business decisions from insightful and in-depth analysis of RAVAX performance.

Order a copy of this report at (Prices start at US $ 3495 for a single user PDF)
http://www.rnrmarketresearch.com/contacts/purchase?rname=312814

1.1 List of Tables
Table 1: Symptoms of RA 20
Table 2: 1987 ACR Diagnostic Criteria for RA 23
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 24
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 27
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 30
Table 6: EULAR 2013 Criteria for RA Remission 31
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 35
Table 8: Leading Branded Treatments for RA 2014 42
Table 9: Unmet Need and Opportunity in RA, 2014 44
Table 10: Comparison of Therapeutic Drug Classes in Development for RA, 2014 62
Table 11: Product Profile - RAVAX 64
Table 12: RAVAX SWOT Analysis, 2014 67
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 78

1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 16
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 19
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 31
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 32
Figure 5: Flowchart for the Management of RA - EULAR 2013 33
Figure 6: RA - Phase II-III Pipeline, 2014 57
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023 61
Figure 8: Clinical and Commercial Positioning of RAVAX 67

Explore more reports on Arthritis Drugs
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/arthritis-drugs